Research in contextEvidence before this studyStatins are among the most widely prescribed drugs worldwide and are generally well tolerated. However, a substantial number of patients discontinues administration of statins because of statin-associated muscle symptoms (SAMS). Currently, the definition, epidemiology, diagnosis and management of SAMS are conflicting, which could be improved by further understanding of the pathophysiology of the symptoms. Beside previously reported mechanisms, such as sarcolemmal cholesterol reduction, isoprenoid depletion and mitochondrial dysfunction, animal studies and clinical observations have suggested the association of high lactate levels with SAMS.Added value of this studyIn this study, C57BL/6 J mice were administrated with lovastatin and blood lactate levels were found increased compared to the control group. Increased lactate was also present in type II predominant glycolytic muscles rather than type I predominant oxidative muscles, associated with compromised maximum swim duration time. *In vitro* studies on muscle cell lines confirmed the enhancement of lactate production by statins, which was not exclusively a secondary effect of impaired mitochondria. Furthermore, we identified the increased expression of muscle specific glycolytic enzyme β-enolase through promoting the degradation of basal p53 is the underlying mechanism, which was dependent on the inhibitory activity on HMG-CoA reductase of statins. Based on these observations, when dichloroacetate (DCA), a reagent effective in treating lactic acidosis, was co-administered, statin-induced lactate elevation and compromised exercise capacity were reverted in mice.Implications of all the available evidenceThese data suggest that the increase of lactate production by statins through p53/β-enolase axis may contribute to SAMS. Co-administration of DCA is a potential avenue to alleviate the symptoms.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Statins, inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, are the most widely prescribed drugs worldwide \[[@bb0005]\]. Millions of people benefit from these lipid-lowering agents to prevent cardiovascular diseases. Although statins are generally well tolerated, patients are suffering from statin-associated muscle symptoms (SAMS), the most common adverse effects of statins. Muscle complaints range from mild myalgia to moderate myopathy and severe rhabdomyolysis with creatine kinase (CK) from normal to marked elevation. The risk of myopathy/rhabdomyolysis is \<0.1%, and that of myalgia is up to 25% in observational studies and 1.4% in placebo controlled randomized trials \[[@bb0010]\]. SAMS causes statin intolerance and lack of adherence, which increases 36% of recurrent myocardial infarction (MI) and 43% of coronary heart disease (CHD) events \[[@bb0015]\]. The underlying mechanism of SAMS remains elusive, although several hypotheses have been proposed and extensively reviewed. Furthermore, efforts to manage SAMS based on previous findings, like supplementation of vitamin D or coenzyme Q10 (CoQ10), are inconclusive \[[@bb0020],[@bb0025]\]. So, new insights into the pathophysiology and treatment of SAMS are warranted.

Lactate is widely accepted as a nociceptive substance. It stimulates afferents during muscle contraction, excites neurons in the locus coeruleus and regulates neuronal plasticity, and enhances the sensitivity of acid-sensing ion channels-3 (ASIC-3), the transducers for nociception and mechanosensation, to low pH \[[@bb0030]\]. Lactate also increases reactive oxygen species (ROS) production, which could directly interact with and activate the nociceptive system \[[@bb0035]\]. Increased tissue/blood concentration of lactate has been associated with pain in both physiological and pathological conditions, such as exercise-induced muscle fatigue, incisional pain, discogenic back pain, chronic Achilles tendinopathy, complex regional pain syndrome (CRPS) and chronic inflammatory pain. Importantly, increased interstitial levels of lactate has been found to be a useful biomarker of chronic musculoskeletal pain, which shares similar symptoms with SAMS including muscle weakness, fatigue, aching, stiffness, cramps, and tenderness. Case reports and clinical studies have revealed that statins could cause lactic acidosis or increased blood lactate/pyruvate ratio or respiratory exchange ratio (RER) \[[@bb0040], [@bb0045], [@bb0050], [@bb0055]\]. Similar results have also been demonstrated in animal studies \[[@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. However, other studies found no obvious elevation of lactate levels with statins treatment \[[@bb0080],[@bb0085]\]. This evidence promotes us to investigate whether statins affect lactate levels and their role in SAMS in mice.

In this study, we demonstrate that increased lactate production is associated with SAMS as manifested by reduced maximum exercise capacity of mice treated with statins. We further report that statins can directly increase lactate production by alleviating the negative regulation of glycolysis by p53, which transcriptionally represses *ENO3* gene that encoding muscle specific β-enolase. Co-administration with dichloroacetate (DCA), an agent effective in lactic acidosis management, promotes lactate recovery and improves statin-induced decrease of exercise capacity. Thus, our study provides a new vision of SAMS.

2. Materials and methods {#s0025}
========================

2.1. Cell culture and reagents {#s0030}
------------------------------

The human rhabdomyosarcoma cell line A-204 and the mouse myoblast C2C12 cell line were obtained from ATCC, and maintained in McCoy\'s 5A medium (Gibco) and Dulbecco\'s modified Eagle\'s medium (Gibco) respectively. C2C12 myoblasts were stimulated to differentiate into myotubes by switching to the medium with 2% horse serum. The human colon cancer HCT116 *SCO2*−/− cell line was a generous gift from Dr. Paul M. Hwang at the National Institutes of Health, and cultured in McCoy\'s 5A medium.

Lovastatin, fluvastatin sodium, simvastatin, rosuvastatin calcium, mevalonic acid sodium, sodium dichloroacetate, coenzyme Q10 (CoQ10) and oligomycin A were purchased from Sigma Aldrich. Pitavastatin and atorvastatin were purchased from Cayman Chemical. Nutlin-3 was purchased from Selleck Chemicals. The doses of statins in cell culture were consistent with previous studies in SAMS \[[@bb0090]\].

2.2. Animal studies {#s0035}
-------------------

All mice were handled and maintained in accordance with the Animal Care and Use Committee of Macau University of Science and Technology. C57BL/6 J female mice were obtained from the Chinese University of Hong Kong and were administrated with lovastatin (50 mg/kg/2 days) alone, similar dose as previous studies in SAMS \[[@bb0075],[@bb0095]\], or together with dichloroacetate (DCA, 40 mg/kg/day) by gavage at 8 weeks old. Maxim swimming capacity was measured as previously reported \[[@bb0100]\]. Briefly, the mice were acclimated to swimming for 5 min/day for 3 days before the formal swimming test. The mice were loaded with a 2 g iron block attached to the tail and the swimming durations to exhaustion were measured in a temperature-controlled (34 °C) tank. The blood lactate concentrations of mice at rest were analyzed using a hand-held lactate analyzer Lactate Scout+ (EKF Diagnostics).

2.3. Glucose, lactate and ATP concentrations assessment {#s0040}
-------------------------------------------------------

Cells with indicated treatments were changed with fresh medium and incubated for an additional 8 h. Culture medium was collected, and glucose and lactate concentrations were determined using the Glucose (GO) Assay Kit (Life technology) and the Lactate Assay Kit (Trinity Biotech) respectively. Intracellular lactate was detected by HPLC (1290 series, Agilent Technologies) coupled with triple TOF 6600 (Q-TOF, AB Sciex). Intracellular ATP level was determined by ATP Determination Kit (Molecular Probes) according to the manufacturer\'s protocol.

2.4. Glucose uptake assay {#s0045}
-------------------------

Cells were seeded in 6-well plates and incubated with fluvastatin for 48 h. The cells were washed three times by PBS and resuspended in 500 μl PBS containing 100 μM 2-N-7-(nitrobenz-2-oxa-1,3-diazol-4-yl) amino-2-deoxy-[d]{.smallcaps}-glucose (2-NBDG, Invitrogen). After 20 min incubation at 37 °C in dark, cells were washed three times with ice-cold PBS and analyzed on flow cytometer (Becton Dickinson).

2.5. Extracellular flux assay {#s0050}
-----------------------------

To evaluate the bioenergetic function of skeletal muscle cells in response to statins, we performed extracellular flux assays using XFp Extracellular Flux Analyzer (Seahorse Bioscience). Cells with indicated treatments were seeded in XFp cell culture miniplates. After incubation overnight, cells were washed with and changed to XF assay medium and incubate at 37 °C in a non-CO~2~ incubator for 1 h. Baseline extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were recorded 6 times with an interval of 6 min. Maximum ECAR was read after administration of oligomycin (10 μM).

2.6. Western blotting {#s0055}
---------------------

Proteins were extracted using ice-cold RIPA buffer supplemented with protease inhibitor cocktail (Roche), separated by 4% - 20% SDS PAGE, transferred to PVDF membrane (Millipore), and visualized by the SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific). Antibodies against p53, β-enolase, HIF 1-α, c-Myc, TIGAR and Glut2 were obtained from Santa Cruz Biotechnology. Antibodies against MDM2, phospho-MDM2 (S166) and Glut1 were obtained from Abcam. Antibodies against Aldolase A, phospho-Akt, HK1, PKM1/2 and LDHA were obtained from Cell Signaling Technology. Antibody against β-actin was obtained from Sigma.

2.7. Immunoprecipitation {#s0060}
------------------------

Cells with indicated treatment were washed with PBS and harvested using ice-cold cell lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1% NP-40) containing protease and phosphatase inhibitors. Cell lysate was then centrifuged and the supernatant was collected. To capture the immune complexes, Protein A/G PLUS-Agarose (Santa cruz) bead slurry (preclear and pre-equilibrated in the cell lysis buffer) was added into the cell lysate and incubated overnight at 4 °C on a rotator. The beads were washed by ice-cold cell lysis buffer and 1× SDS-PAGE sample loading buffer was added. Centrifuged and collected the supernatant carefully. The immunoprecipitate (supernatant) was load onto an SDS-PAGE gel for western blotting analysis.

2.8. Identification of p53 repressive response elements and chromatin immunoprecipitation (ChIP) assay {#s0065}
------------------------------------------------------------------------------------------------------

We used UCSC Genome Browser (<http://genome.ucsc.edu/>) to obtain the human *ENO3* genomic sequence. The potential p53 repressive response elements (p53RREs), which are consisting of four canonical p53-binding sites (5'-RRRCW-3′) arranged head to tail and matching \>90%, were identified by Vector NTI Advance 10 software (Invitrogen).

ChIP assay was performed with ChIP-IT Express (Active Motif) following the manufacturer\'s protocol. A-204 cells were fixed with 1% formaldehyde on a shaking platform for 10 min at room temperature following by sonication to shear the chromatin. Samples were immunoprecipitated with mouse monoclonal anti-p53 antibody or control mouse IgG serum (10 μg/ml) for PCR amplification. *CD44* served as the positive p53RRE control \[[@bb0105]\].

Sequences of RT-PCR primer pairs for the putative p53RREs:

ENO3-RRE1 (Foward:5′-CAGGCAATGTCTGGATCACCG-3′, Reverse:5′-CTGACTGCGAAGAAACCCAAAG-3′)

ENO3-RRE2 (Foward:5′-CCTGTCTAAATTCGTTTCCTGTCC-3′, Reverse:5′-CACCCCAGGATTACATTCCC-3′)

ENO3-RRE3 (Foward:5′-TTGACCTTTGGTAAGGGGGC-3′, Reverse:5′-AGCCAATACCATGCTCACCC-3′)

CD44-RRE (Foward:5′-TTTACGGTTCGGTCATCCTC-3′, Reverse:5′-TGCTCTGCTGAGGCTGTAAA-3′)

2.9. Promoter reporter assay {#s0070}
----------------------------

Oligonucleotides containing the putative *ENO3* p53RRE3 or the mutated p53RRE3 sequences were annealed and cloned into the pNL3.2 \[NlucP/minP\] nanoluciferase vector (Promega) between *Sac*I and *Xho*I restriction sites. ENO3-p53RRE3-WT-F:5′-CGGGGTGAGCTGACACTGTCCCAGCTGCCACCTAGACTCGGAGCTCCATC-3′, ENO3-p53RRE3-WT-R:5′-TCGAGGATGGAGCTCCGAGTCTAGGTGGCAGCTGGGACAGTGTCAGCTCACCCCGAGCT-3′, ENO3-p53RRE3-MUT-F:5′-CGGGGTGAGCTGACACTGTCCCAGCTGCCACCTAGATCCGGACCTCCATCC-3′, ENO3-p53RRE3-MUT-R:5′-TCGAGGATGGAGGTCCGGATCTAGGTGGCAGCTGGGACAGTGTCAGCTCACCCCGAGCT-3′.

A-204 cells were co-transfected with the reporter plasmids and the transfection efficiency control plasmid (pGL4.54 \[luc2/TK\]) containing TK promoter and firefly luciferase. The luminescence activities of the firefly luciferase and the nanoluciferase were sequentially measured with the Nano-Glo® Dual-Luciferase® Reporter Assay System following the manufacturer\'s instruction (Promega).

2.10. Lentivirus mediated mRNA knockdown and cDNA expression {#s0075}
------------------------------------------------------------

Oligonucleotides containing the p53 and HMGCR shRNA sequences were cloned into the pLKO.1 plasmid (Addgene, 10,878) and verified by sequencing. Plasmid containing the non-specific shRNA (SHC002, Sigma) was used as a negative control for gene knockdown.

shp53-1:5′-CCGGCGGCGCACAGAGGAAGAGAATCTCGAGATTCTCTTCCTCTGTGCGCCGTTTTTG-3′, shp53-2:5′-CCGGGTCCAGATGAAGCTCCCAGAACTCGAGTTCTGGGAGCTTCATCTGGACTTTTTG-3′, shHMGCR-1:5′-CCGGCTATGATTGAGGTCAACATTACTCGAGTAATGTTGACCTCAATCATAGTTTTTG-3′, shHMGCR-2:5′-CCGGGGTTCTAAAGGACTAACATAACTCGAGTTATGTTAGTCCTTTAGAACCTTTTTG-3′.

The empty plasmid pLenti-CMV and the plasmid containing *ENO3* cDNA (accession number NM_001976) were obtained from Public Protein/Plasmid Library. Lentiviruses were generated by co-transfected of lentiviral plasmids and the MISSION packing mix (Sigma) into HEK293T cells according to the manufacturer\'s protocol. A-204 cells were transduced with lentivirus for mRNA knockdown or cDNA expression and selected with puromycin before further analysis.

2.11. Real-time PCR quantitation {#s0080}
--------------------------------

Cellular mRNA was extracted using the Dynabeads mRNA Direct Kit (Life Technologies) and cDNA was synthesized by the SuperScript III reverse transcriptase (Life Technologies) according to the manufacturer\'s instructions. Quantitative real-time PCR analysis was performed on the ViiA™ 7 Real-Time PCR System (Applied Biosystems). Cellular mRNA expression levels of target genes were normalized to the eukaryotic translation initiation factor (EIF3S5).

2.12. Statistical analyses {#s0085}
--------------------------

Data are shown as the mean ± SD unless otherwise stated. Statistical analyses between two groups were performed by two-tailed distribution Student\'s *t*-test using Microsoft Excel. When more than two groups were compared, data were analyzed by one-way ANOVA using GraphPad Prism 5 software. When a significant F ratio was confirmed, the difference was further analyzed by Tukey\'s test. Significant differences were indicated as \*(*P* \< .05), \*\*(*P* \< .01) or \*\*\*(*P* \< .001) according to the level of significance.

3. Results {#s0090}
==========

3.1. Lovastatin attenuates exercise capacity in mice and increases blood and muscle lactate levels {#s0095}
--------------------------------------------------------------------------------------------------

Decreased exercise capacity has been reported as the behavioral feature in animal models of SAMS \[[@bb0075],[@bb0110],[@bb0115]\]. To validate the mouse model in this study, we performed swimming endurance test in mice treated with lovastatin. As expected, the maximum swim times were significantly reduced by 23.1% ± 8.6% (*P* = .016, Student\'s *t*-test) in mice treated with lovastatin for 30 days comparing to the control group ([Fig. 1](#f0005){ref-type="fig"}a). The loss of exercise capacity returned to normal 2 weeks after drug withdraw ([Fig. 1](#f0005){ref-type="fig"}a), which is complied with the clinical diagnostic criteria of SAMS \[[@bb0120]\]. Blood lactate was increased by 23% ± 10.5% (*P* = .045, Student\'s *t*-test) at 30 days under resting conditions with lovastatin treatment ([Fig. 1](#f0005){ref-type="fig"}b). The increased blood lactate levels persisted as long as the treatment continues up to 30 weeks (Supplemental Fig. 1a). In accordance with recovered exercise capacity, stopping administration of lovastatin decreased blood lactate levels back to normal ([Fig. 1](#f0005){ref-type="fig"}b).Fig. 1Lovastatin attenuates exercise capacity in mice and increases blood and muscle lactate levels. (a) Maximum swimming duration times of C57BL/6 J mice administered with lovastatin for 30 days and after the drug withdrawn for an additional 14 days (*n* = 10 each group). (b) Resting blood lactate levels before the swimming test (n = 10 each group). (c) Lactate concentrations in gastrocnemius (GAS), tibialis anterior (TA) and soleus (SOL) muscles of mice administered with lovastatin for 30 days (n = 10 each group). Data are shown as mean ± SD,\**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 (Student\'s *t*-test).Fig. 1

As skeletal muscles are the lesion sites affected by SAMS and also the major tissues producing lactate, we measured the effect of lovastatin on lactate concentrations in different muscles. We found that lactate levels were significantly higher in type II predominant glycolytic muscles gastrocnemius (GAS) and tibialis anterior (TA) ([Fig. 1](#f0005){ref-type="fig"}c). There was a trend, although not significant, of increased lactate in the other two glycolytic muscles extensor digitorum longus (EDL) plantaris (PLA) (Supplemental Fig. 1c), suggesting that statins may enhance glycolysis resulting in increased lactate production. In line with this idea, there was no significant change in soleus (SOL), which is type I predominant oxidative muscle ([Fig. 1](#f0005){ref-type="fig"}c).

There was no elevation of plasma CK levels in mice treated with lovastatin (Supplemental Fig. 1b), indicating no severe rhabdomyolysis was induced in this study. This was further confirmed by histological analysis with GAS and TA muscles showing no obvious morphologic changes (Supplemental Fig. 1d). This discrepancy between functional changes and morphological changes in statin treated mice was also reported previously \[[@bb0095]\]. Furthermore, lovastatin treatment neither changed the body weight significantly nor caused any obvious physical/health problems of the mice. Taken together, these results imply that increased lactate levels are associated with SAMS, especially mild myalgia.

3.2. Statins increase lactate production in cultured skeletal muscle cell lines {#s0100}
-------------------------------------------------------------------------------

To verify the observed increased lactate levels in mice with lovastatin treatment, we measured lactate production in mouse C2C12 myotubes and human A-204 rhabdomyosarcoma cell lines, both were widely used in muscle biology studies. As shown in [Fig. 2](#f0010){ref-type="fig"}a, fluvastatin augmented lactate released into the culture medium 12%--56% in A204 cells and 19%--67% in C2C12 myotubes respectively at the indicated concentrations. This was further confirmed by the elevated intracellular levels of lactate ([Fig. 2](#f0010){ref-type="fig"}b), as well as by the increased extracellular acidification rate (ECAR) at both baseline and maximum level stimulated by mitochondrial ATP synthase inhibitor oligomycin ([Fig. 2](#f0010){ref-type="fig"}C). Increased lactate production was in accordance with increased glucose consumption as evidenced by direct measurement of residue glucose in the medium (Supplemental Fig. 2a) and by flow cytometric analysis of the fluorescent deoxyglucose analog 2-NBDG (Supplemental Fig. 2b).Fig. 2Statins increase lactate production in cultured skeletal muscle cell lines. (a) Dose-response of fluvastatin treatment for 48 h on lactate production in A-204 cells and C2C12 myotubes (*n* = 3). (b) Effect of fluvastatin (10 μM) treatment for 48 h on intracellular lactate levels normalized to the untreated control cells (n = 3). (c) Baseline and maximum (stimulated by oligomycin) extracellular acidification rate (ECAR) after fluvastatin (10 μM) treatment for 48 h (n = 3). Insert is the average normalized to control in baseline. (d) Lactate production after lentivirus-mediated knockdown of HMGCR in A-204 cells cultured for 48 h (n = 3). HMGCR protein assessed by western blotting. (e) Effect of mevalonate (MVA, 200 μM) on fluvastatin-induced (10 μM) lactate production in A-204 cells (*n* = 3). (f) Lactate production in A-204 cells exposed to atorvastatin (Atr), pitavastatin (Pit), simvastatin (Sim), rosuvastatin (Ros), and lovastatin (Lov) at 10 μM for 48 h (*n* = 3). (g) Baseline and maximum (stimulated by oligomycin) extracellular acidification rate (ECAR) in HCT116 *SCO2*−/− cells with fluvastatin (10 μM) treatment for 48 h (n = 3). Insert is the average normalized to control in baseline. (h) Effect of Coenzyme Q10 (1 μM) on baseline extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) following fluvastatin (10 μM) treatment for 48 h (n = 3). Seahorse XF Analyzer assay data are shown as mean ± SEM, other data are shown as mean ± SD, \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001 (Student\'s *t*-test).Fig. 2

Statins inhibit the rate-limiting enzyme, HMG-CoA reductase (HMGCR), in the cholesterol synthesis pathway. To confirm the specificity of the elevated lactate production with the inhibition of HMGCR by statins, we carried out lentivirus-mediated knockdown of the enzyme and found increased lactate productions by two distinct lentiviral hairpins ([Fig. 2](#f0010){ref-type="fig"}d). Supplementation of mevalonic acid (MVA), the immediate product of HMGCR, restored statin-induced lactate levels ([Fig. 2](#f0010){ref-type="fig"}e and Supplemental Fig. 2c). Furthermore, other statins currently used in the clinic also increased lactate production in A-204 cells ([Fig. 2](#f0010){ref-type="fig"}f) and in C2C12 myotubes (Supplemental Fig. 2d).

Statins affect mitochondrion functions through multiple mechanisms, as extensively reviewed \[[@bb0125]\]. Indeed, fluvastatin inhibited oxygen consumption rate (OCR) and decreased intracellular ATP levels in muscle cells (Supplemental Fig. 2f and Supplemental Fig. 2e). The question of the observed increased lactate production is whether it is the direct effect of statins or the metabolic compensatory effect of impaired mitochondria. After administration of oligomycin, the compound inhibiting respiration, increased ECAR ([Fig. 2](#f0010){ref-type="fig"}c) with fluvastatin treatment persisted. To further clarify this question, we took advantage of the human colon cancer cell line HCT116 depleted of *SCO2* gene, which is deficient of mitochondrial respiration \[[@bb0130]\]. As expected, treatment with fluvastatin had no effect on the OCR of the cells (Supplemental Fig. 2 g). However, fluvastatin still increased lactate production in HCT116 *SCO2*−/− cells despite the non-functional mitochondria ([Fig. 2](#f0010){ref-type="fig"}g). CoQ10 rescued the oxidative metabolism in muscle cells treated with fluvastatin ([Fig. 2](#f0010){ref-type="fig"}h), which is consistent with the previous studies \[[@bb0090]\]. However, the ECAR remained the same as fluvastatin treated regardless of CoQ10 supplementation ([Fig. 2](#f0010){ref-type="fig"}h). Our findings indicate that the enhanced lactate production cannot be attributed exclusively as a secondary effect of impaired mitochondria.

3.3. p53/β-enolase axis mediates statin-induced lactate production {#s0105}
------------------------------------------------------------------

Lactate is the end product of anaerobic glycolysis. In order to find out the underlying mechanism of increased lactate production with statins treatment, we checked the expression levels of enzymes in the glycolysis pathway as well as the known upstream regulators. We did not observe significant changes in glycolysis enzymes, like hexokinase-1 (HK1), aldolase A, pyruvate kinase isozymes M1/M2 (PKM1/M2) and lactate dehydrogenase A (LDHA) (Supplemental Fig. 3). But it was interesting that β-enolase increased with fluvastatin treatment both dose- and time-dependently ([Fig. 3](#f0015){ref-type="fig"}a and [3](#f0015){ref-type="fig"}b). β-enolase is the muscle-specific isoform of enolases, converting 2-phosphoglycerate to phosphoenolpyruvate in the glycolysis pathway, and is expressed higher in type II muscle fibers than type I fibers \[[@bb0135]\]. Consistent with being the muscles with significantly increased lactate ([Fig. 1](#f0005){ref-type="fig"}c), glycolytic type II fibers GAS and TA exhibited higher β-enolase proteins following lovastatin treatment ([Fig. 3](#f0015){ref-type="fig"}c). Exogenous expression of β-enolase significantly increased lactate production in A-204 cells ([Fig. 3](#f0015){ref-type="fig"}d).Fig. 3p53/β-enolase axis mediates statin-induced lactate production (a) Dose effect (48 h) and (b) time-course (10 μM) of fluvastatin on the protein levels of p53 and β-enolase in A-204 cells and C2C12 myotubes. (c) p53 and β-enolase protein levels in gastrocnemius (GAS) and tibialis anterior (TA) muscles of mice treated with lovastatin for 30 days. (d) Lactate production in A-204 cells exogenously expression of β-enolase (*n* = 3). (e) Lactate production after lentivirus-mediated knockdown of p53 in A-204 cells (n = 3). p53 and β-enolase protein assessed by western blotting. (f) p53 and β-enolase protein in A-204 cells exposed to atorvastatin (Atr), pitavastatin (Pit), simvastatin (Sim), rosuvastatin (Ros), and lovastatin (Lov) at 10 μM for 48 h. (g) p53 and β-enolase protein in A-204 cells after lentivirus-mediated knockdown of HMGCR. (h) Effect of mevalonate (MVA, 200 μM) on the protein level of p53 and β-enolase following fluvastatin (10 μM) treatment for 48 h. Data are shown as mean ± SD, \**P* \< .05, \*\*\**P* \< .001 (Student\'s t-test).Fig. 3

We then checked protein levels of well-characterized upstream regulators of glycolysis including hypoxia-inducible factor 1- α (HIF 1-α), c-Myc, phospho-Akt and TP53-inducible glycolysis and apoptosis regulator (TIGAR), and there were no significant changes of these proteins (Supplemental Fig. 3). The lack of consistency of induced phospho-Akt by stains with previous publication probably dues to different experiment systems \[[@bb0140]\]. However, tumor suppressor p53, which has been found regulating glycolysis through multiple pathways in last decade \[[@bb0145]\], was significantly decreased by statins in both muscle cells ([Fig. 3](#f0015){ref-type="fig"}a and [3](#f0015){ref-type="fig"}b) and tissues ([Fig. 3](#f0015){ref-type="fig"}c). Our finding implies the possible regulation of β-enolase by p53 following statin treatment. To verify this observation, p53 was knocked down by lentivirus-mediated shRNA in A-204 cells and we found that reduced expression of p53 proteins caused the increment of β-enolase and lactate production ([Fig. 3](#f0015){ref-type="fig"}e). The correlation of p53 and β-enolase was reproduced with other statins ([Fig. 3](#f0015){ref-type="fig"}f). The specificity of the regulation of p53/β-enolase axis by the inhibition of HMGCR with statins was confirmed by both HMGCR knockdown ([Fig. 3](#f0015){ref-type="fig"}g) and MVA supplementation experiments ([Fig. 3](#f0015){ref-type="fig"}h) in A-204 cells.

To understand the underlying mechanisms of statin-induced p53 down-regulation, we first measured the mRNA levels of p53 in A-204 cells. There were no obvious changes neither with fluvastatin treatment nor with HMGCR knockdown ([Fig. 4](#f0020){ref-type="fig"}a), indicating that statins may affect p53 protein stability. Statins have been reported to increase phosphorylation of MDM2 at Ser166, which can promote p53 degradation \[[@bb0150]\]. Indeed, fluvastatin increased MDM2 phosphorylation dose-dependently ([Fig. 4](#f0020){ref-type="fig"}b) and enhanced the binding of MDM2 with p53 proteins ([Fig. 4](#f0020){ref-type="fig"}c). Inhibition of MDM2-p53 interaction by nutlin nullified the effect of fluvastatin on the protein levels of p53 and β-enolase ([Fig. 4](#f0020){ref-type="fig"}d).Fig. 4Fluvastatin promotes p53 degradation *via* enhanced MDM2 phosphorylation. (a) *p53* mRNA levels with fluvastatin (10 μΜ) treatment at the indicated time (left panel) and after HMGCR knocking down (right panel) in A-204 cells (n = 3). (b) Total and phosphorylated MDM2 (Ser166) protein levels with fluvastatin (10 μΜ) treatment in A-204 cells for 48 h. (c) Cytosolic extract of A-204 cells treated with fluvastatin (10 μΜ) for 48 h were immunoprecipitated (IP) with control IgG or anti-p53 antibody. MDM2 and p53 proteins assessed by western blotting. (d) p53 and β-enolase protein in A-204 cells exposed to Nutlin-3 (10 μΜ) and fluvastatin at indicated concentrations for 48 h. Data are shown as mean ± SD.Fig. 4

These data suggest that statins regulate lactate productions through the p53/β-enolase axis.

3.4. p53 transcriptional represses *ENO3* {#s0110}
-----------------------------------------

The next crucial question to address is how the loss of basal p53 by statins down regulates β-enolase. As a transcription factor, p53 represses gene expression through binding to the DNA motif consisting of four canonical p53-binding sites arranged head to tail (p53RRE) \[[@bb0105],[@bb0155]\]. We scanned the *ENO3* promoter (−2000 to +100) and found 3 putative p53RRE sites with \>90% identity ([Fig. 5](#f0025){ref-type="fig"}a). We first carried out chromatin immunoprecipitation (ChIP) in A-204 cells to test whether p53 can bind to these putative p53RRE sites. Only p53RRE3, the one with highest homology (95% identity) to the p53 repressive consensus sequence, was pulled down by the anti-p53 antibody comparing with nonspecific control IgG ([Fig. 5](#f0025){ref-type="fig"}b). A specific p53 repressive binding site in the *CD44* gene served as the positive control. The repressive effect of basal p53 on p53RRE3 was tested by promoter reporter assay. As shown in [Fig. 5](#f0025){ref-type="fig"}c, the luciferase reporter construct containing three point mutations in p53RRE3 (RRE3-MUT) displayed significant higher activity than the wild type construct (RRE3-WT). In addition, knockdown of endogenous p53 increased the luciferase signal ([Fig. 5](#f0025){ref-type="fig"}c). Finally, the mRNA levels of *ENO3* were significantly elevated when knocking down of either *p53* or *HMGCR*, further verified the transcriptional repressive activity of baseline levels of p53 on *ENO3* and the suggested signal axis of statins on lactate production ([Fig. 5](#f0025){ref-type="fig"}d).Fig. 5p53 transcriptional represses *ENO3*. (a) The putative p53 repressive response elements (p53RREs) in human *ENO3* promoter, relative to bp +1 position of the transcription start site (TSS), are shown in bold. The matching consensus p53RRE bases are shown in uppercase characters. ID% indicates the identity. R, purine; W, A, or T base. (b) Chromatin immunoprecipitation (ChIP) assay to present the interaction between *ENO3* p53RREs and p53 protein in A-204 cells. Chromatin from A-204 cells was immunoprecipitated (IP) with either anti-p53 antibody or control IgG. The obtained DNA fragments were amplified by PCR using a set of primer pairs surrounding the p53RRE sites in the *ENO3* promoter. The p53RRE of *CD44* gene was used as a positive control. (c) The point mutations introduced into p53RRE3 are shown in underscore characters. Luciferase reporter assay of wild type (RRE3-WT), mutated (RRE3-MUT) and knockdown of p53 (RRE3-WT/shp53) of *ENO3* p53RRE3 in A-204 cells (*n* = 3). (d) *ENO3* mRNA level in response to p53 and HMGCR knocking down in A-204 cells (n = 3). Data are shown as mean ± SD, \**P* \< .05, \*\*\**P* \< .001 (Student\'s *t*-test).Fig. 5

3.5. Dichloroacetate decreases lactate accumulation and improves decline in exercise capacity in mice treated with lovastatin {#s0115}
-----------------------------------------------------------------------------------------------------------------------------

Dichloroacetate (DCA) is a potent inhibitor of pyruvate dehydrogenase kinase (PDK), resulting in the inhibition of lactate production, and has been shown to be effective in the treatment of patients with lactic acidosis \[[@bb0160]\]. DCA is also able to reduce muscle lactate accumulation in both animals and humans \[[@bb0165]\]. So, we reasoned that DCA may be able to attenuate SASM by decreasing lactate accumulation in muscles. To test this hypothesis, we first measured the effect of DCA on extracellular lactate levels in muscle cells. Supplementation of DCA eliminated the increased lactate production by fluvastatin (25% and 45% decrease compared to control and fluvastatin single treatment respectively), consisting with the potent glycolysis inhibitory activity of DCA ([Fig. 6](#f0030){ref-type="fig"}a). Next, DCA was co-administrated with lovastatin in mice for 30 days. The swimming endurance was significantly improved by DCA ([Fig. 6](#f0030){ref-type="fig"}b), in line with the recovered lactate levels in blood ([Fig. 6](#f0030){ref-type="fig"}c) and in GAS and TA muscles ([Fig. 6](#f0030){ref-type="fig"}d).Fig. 6Dichloroacetate antagonizes statin-induced lactate accumulation and improves mice exercise capacity. (a) Effect of dichloroacetate (DCA, 10 mM) on fluvastatin-induced lactate production in muscle cells (n = 3). (b) Maximum swimming duration times of C57BL/6 J mice co-administered with lovastatin and DCA for 30 days (*n* = 10 each group). (c) Resting blood lactate levels of C57BL/6 J mice co-administered with lovastatin and DCA for 30 days (n = 10 each group). (d) Lactate concentrations in gastrocnemius (GAS) and tibialis anterior (TA) muscles of C57BL/6 J mice co-administered with lovastatin and DCA for 30 days (n = 10 each group). Data are shown as mean ± SD, \**P* \< .05, \*\**P* \< .01 (one-way ANOVA, Tukey\'s test).Fig. 6

4. Discussion {#s0120}
=============

Currently, the definition, epidemiology, diagnosis and management of SAMS are conflicting, which could be improved by further understanding of the pathophysiology of the symptoms. Several theories have been proposed, including sarcolemmal cholesterol reduction, isoprenoid depletion and mitochondrial dysfunction \[[@bb0170]\]. However, it has been demonstrated that nonstatin lipid-lowering agents fibrates induced myopathy through different pathways \[[@bb0175]\], which questions the sarcolemmal cholesterol reduction theory. As the target of RhoA, which is activated by prenylation, Akt phosphorylation is decreased with statin treatment \[[@bb0180]\]. But, our results with unchanged phosphor-Akt (Supplemental Fig. 3) and published data showing an increase with statin treatment \[[@bb0140]\] makes the isoprenoid depletion theory more complicated. Mitochondrial dysfunction is the most privileged hypotheses of SAMS. Nonetheless, it has been challenged \[[@bb0185], [@bb0190], [@bb0195], [@bb0200]\], and supplementation of CoQ10 is inconclusive. Here, we provided another possibility that increased lactate, an important nociceptive substance in muscle complaints, may contribute to SAMS. It is supported by the fact that exercise exacerbates muscle syndromes induced by statins \[[@bb0205]\], as exercise will cause additional lactate accumulation. It is also consistent with previous findings that glycolytic muscles are more affected by statins \[[@bb0210]\]. At the meantime, we recognized the intricacy of the topic, with many studies showing little impact of statins on muscle symptoms \[[@bb0215]\], the lack of appropriate animal models \[[@bb0220]\], and studies showing no obvious elevation of lactate levels with statins treatment \[[@bb0080],[@bb0085]\]. However, our findings represent a new insight into this field, and may be complementary to other hypotheses in different forms/contexts of SAMS. Together with the findings that statins inhibit monocarboxylate transporter 1 and 4 (MCT1 and MCT4) which are responsible for lactate uptake \[[@bb0180]\], our results do suggest clinical studies of the association of blood lactate levels with SAMS to be carried out.

Apart from the canonical tumor suppressive activities, the tumor suppressor p53 plays important roles in maintaining cellular health and function in skeletal muscle \[[@bb0225]\]. In this study, we found that statins decreased basal p53 levels through repressive regulation of β-enolase, resulting in compromised exercise capacity, which is consistent with previous findings in p53 knockout mice \[[@bb0230],[@bb0235]\]. It has been reported that patients carrying inherited β-enolase deficiency present with a mild myopathy similar to some forms of SAMS \[[@bb0240],[@bb0245]\]. The patients were glycolytic defective, which prevents energy production, similar to other inherited metabolic myopathies. While in our study, statin stimulated β-enolase promotes the nociceptive substance lactate production, resulting in muscle symptoms. Thus, it is possible that abnormal β-enolase promotes muscle symptoms at either insufficient or excessive levels under different mechanisms.

In this study, we showed that DCA reverted lactate elevation in blood and muscles and improved exercise capacity in mice treated with lovastatin, indicating its possible application against SAMS. In addition, DCA has been reported to increase mitochondrial oxidative metabolism leading to an improved cellular energy state in skeletal muscles \[[@bb0250]\], and revert simvastatin-induced CK elevation through inhibition of forkhead box protein O (FOXO) mediated proteolysis \[[@bb0255]\]. However, it is should be noted that other pharmacological effects of DCA, such as the non-competitive inhibitory effect on HMG-CoA reductase and induction of peripheral neuropathy, are potential confounding factors that may intervene in its use in SAMS \[[@bb0160]\]. Furthermore, DCA inhibits its own metabolism enzyme glutathione transferase zeta 1 (GSTZ1) in a chloride-dependent manner, resulting in delayed elimination upon repeated doses \[[@bb0160]\]. In the sarcoplasma, statins can affect the chloride channel conductance \[[@bb0180]\], raising another concern about drug interactions between statins and DCA. So caution should be taken in choosing the appropriate doses before the clinical trials of DCA on SAMS.

Appendix A. Supplementary data {#s0145}
==============================

Supplementary materialImage 1
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